EGFR and non-small cell lung carcinoma: Our research revealed that β-elemene, when used alongside gefitinib, diminishes cell viability and enhances apoptosis in gefitinib-resistant EGFR-mutant NSCLC cells, specifically HCC827/GR and PC9/GR.